web analytics
4.6 C
Munich
Sunday, April 18, 2021

Mfusion; the Rise of Biolife Sciences Inc (OTCMKTS: BLFE)

Biolife Sciences Inc (OTCMKTS: BLFE) is one exciting stock that has proven to be one of the biggest runners in recent small caps history skyrocketing from $0.037 lows last summer to recent highs of $4.33 per share. Since a brief dip to $1 BLFE is once again running northbound in a hurry. The stock has just 4 million shares in the float.

Biolife has seen a wild ride as the Company’s products designed to fight covid-19 using its Mfusion Technology which leverages the natural antimicrobial benefits of copper ions and has been shown to kill 99.99% of bacteria, fungi and viruses. The Company’s FebriDx(R) ultra-rapid, disposable, point-of-care test device identifies clinically significant Acute Respiratory Infections (ARI) and differentiates viral from bacterial causes. Approved by Health Canada for SARS-CoV-2 (COVID-19) virus testing and other viral and bacterial infections, the test itself takes only 30 seconds and provides non-invasive test results for ARIs within ten (10) minutes.

Biolife Sciences Inc (OTCMKTS: BLFE) operating out of Toronto, Ontario, Biolife specializes in moving innovative products from the lab or small-scale production into wider market adoption. Its core business develops, licenses and distributes antimicrobial products, non-contact human temperature screening technology, and touchless vending/marketplaces. One of BioLife Sciences’ core building block strategies is to develop, partner and assist innovative companies with the commercialization of leading-edge technologies.

Recently the Company launched its new antimicrobial air filter technology. BioLife Antimicrobial Air Filters provide consumers with the ability to help sanitize the air in their homes or workspaces, while providing continuous, long-lasting protection for months. The fabric-based BioLife Antimicrobial Copper Air Filter utilizes the company’s proprietary Mfusion Technology. Mfusion Technology infuses copper metal ions into every sub-bundle of the fabric filter, resulting in natural protection against bacteria and germs, which normally thrive when circulating in an enclosed room, or building.  The fabric helps to block out airborne particles, while any germs or viruses which are trapped in the filter fabric will come in contact with the copper ions and become deactivated over time.

According to Report Linker the global market for disinfectants estimated at US$5.4 Billion in the year 2020, is projected to reach a revised size of US$8.3 Billion by 2027, growing at CAGR of 6.2% over the period 2020-2027. BioLife has acquired new technologies and processes that are implemented to mitigate the spread of harmful microbes and viruses using innovative solutions.

To Find out the inside Scoop on VISM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

BLFE

Biolife has also developed Hand Sanitizer Gels are NPN-Licensed and Health Canada approved alcohol-based sanitizer. It provides a safe and effective way to sanitize your hands when soap and water are unavailable. All BioLife Hand Sanitizer follows the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) guidelines for effective hand hygiene recommendations. The Company recently reported the sale of over 250,000 units of its Hand Sanitizer. Sales were conducted through BioLife-owned brands and their extensive network of wholesalers and distributors.  The Company now offers intelligent, touchless vending machines and marketplaces as part of its lineup of innovative digital products designed to assist consumers in the wake of the recent ongoing health crisis. BioLife’s vending machines will help to eliminate physical touchpoints to better serve customers, who will now be able to remotely view menus of available options on an app prior to making a secure payment on their smartphone. Intelligent touchless vending and marketplaces provides consumers with a wide range of high-quality personal protection equipment (PPE) and a diverse offering of antimicrobial and health care products. Biolife has introducted non-contact human temperature screening to its lineup of products designed to provide businesses with cost-effective solutions to successfully navigate through the current health crisis.

On October 26 Biolife announced the immediate commercial availability of the FebriDx(R) – its ultra-rapid, disposable, point-of-care test device that identifies a clinically significant Acute Respiratory Infection (ARI) and differentiates viral from bacterial causes. Approved by Health Canada for SARS-CoV-2 (COVID-19) virus testing and other viral and bacterial infections, the test itself takes only 30 seconds and provides non-invasive test results for ARIs within ten (10) minutes.

The FebriDx(R), available from BioLife Sciences, can be administered by trained professionals at places like: pharmacies, walk-in clinics, long-term care homes, workplaces, and doctors’ offices without the need for a laboratory to determine if someone is infected with the virus. A healthcare worker performs a fingerstick blood sample during a patient’s initial workup. Upon generating the results, a treatment plan can be established during the patient’s initial visit or on-site, as opposed to waiting for 24 hours or longer. In the event of a positive COVID-19 test, rapid triaging can begin to successfully isolate patients and prevent further spread of the infection.

For more on BLFE subscribe Right Now!

Currently running northbound in a hurry since reversing off $1 BLFE is an exciting story developing in small caps; Biolife has seen a wild ride as the Company’s products designed to fight covid-19 using its Mfusion Technology which leverages the natural antimicrobial benefits of copper ions and has been shown to kill 99.99% of bacteria, fungi and viruses. The Company’s FebriDx(R) ultra-rapid, disposable, point-of-care test device identifies clinically significant Acute Respiratory Infections (ARI) and differentiates viral from bacterial causes. Approved by Health Canada for SARS-CoV-2 (COVID-19) virus testing and other viral and bacterial infections, the test itself takes only 30 seconds and provides non-invasive test results for ARIs within ten (10) minutes. We will be updating on BLFE when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with BLFE.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in BLFE either long or short and we have not been compensated for this article.

 

 

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.